Pharmaceutical News

RSS

Microbia creates carotenoids for food ingredient and nutritional supplement markets

Microbia, Inc., an emerging leader in the production of sustainable specialty ingredients and biomaterials, today announced that it has achieved an important milestone in creating its line of naturally derived carotenoids for the food ingredient and nutritional supplement markets.

7 Jan 2010

CEI releases new diabetes market forecast study

Since 2008, Cutting Edge Information has developed forecasting data for the diabetes treatment market. The new report -- "Diabetes Market Forecast to 2015" -- provides a deep analysis of the relevant clinical, commercial, and market trends affecting diabetes therapeutics today and their impact leading into the next decade. In addition to detailed drug, class, and company profiles, the study includes primary research findings generated from survey data and interviews with leading physicians and marketing executives.

7 Jan 2010

Drug companies still under great and growing pressure to bring more products to market

Although drug developers are improving R&D efficiency, in part by terminating more unpromising drugs earlier in development, their continued success will depend on how well they partner with other firms at specific points on the development spectrum, according to the Tufts Center for the Study of Drug Development.

7 Jan 2010

ProFibrix B.V. receives loan up to $7.4 million to develop its new hemostat Fibrocaps

ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced that SenterNovem, an agency of the Dutch Ministry of Economic Affairs, has granted the company a loan under its new Innovation Credit scheme of potentially up to EUR 5 million to finance the further clinical development of its unique new hemostat Fibrocaps(TM).

7 Jan 2010

Teva Pharmaceutical Industries enters into two definitive agreements with AstraZeneca

Teva Pharmaceutical Industries Ltd. announced today that it has entered into two definitive agreements with AstraZeneca to settle patent litigation regarding Teva’s U.S. generic versions of AstraZeneca’s Prilosec® (omeprazole) and Nexium® (esomeprazole), including all claims for patent infringement and damages.

7 Jan 2010

Nutrient mix shows potential to improve memory in Alzheimer's patients

In the early stages of Alzheimer's disease, patients typically suffer a major loss of the brain connections necessary for memory and information processing. Now, a combination of nutrients that was developed at MIT has shown the potential to improve memory in Alzheimer's patients by stimulating growth of new brain connections.

7 Jan 2010

Flu vaccine safe but ineffective for RA patients treated with rituximab

Rheumatoid arthritis (RA) patients are partially protected by the influenza vaccine 6-10 months after treatment with rituximab. Researchers determined that while the flu vaccine is safe, it is ineffective for RA patients in the first 6 months following rituximab treatment.

7 Jan 2010

Bogus drug manufactures embrace new tactics to dupe consumers

Manufacturers of counterfeit prescription drugs are embracing new tactics to deal with an estimated $75-billion-year market in knockoffs, a battle that is far from being won.

7 Jan 2010

Watson Laboratories files ANDA to seek FDA's approval to market Nuvigil

Watson Pharmaceuticals, Inc., a leading global specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc., a Nevada Corporation, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market its 50 mg, 100 mg, 150mg, 200 mg, and 250mg strength armodafinil tablets prior to the expiration of patents owned by Cephalon France.

7 Jan 2010

Canada supports Mexico's pandemic response efforts

The Honourable Leona Aglukkaq, Minister of Health, on behalf of the Government of Canada, has announced it will be providing five million doses of H1N1 flu vaccine to Mexico to help bridge that country's immediate pandemic vaccine requirements. This is not a donation. Mexico will replenish Canada's H1N1 vaccine supply by March 31, 2010.

7 Jan 2010

Developing countries reassess need for donated H1N1 vaccine

As the number of H1N1 (swine flu) cases in some regions of the world continues to fall, developing countries scheduled to receive donated H1N1 (swine flu) vaccines from the WHO are reassessing just how many vaccines their countries need, the Canadian Press reports.

6 Jan 2010

Pfizer and Strides Arcolab announce new collaboration

Pfizer (NYSE: PFE) and Strides Arcolab today announced a new collaboration, wherein Pfizer will commercialize off-patent sterile injectable and oral products in the United States through its Established Products Business Unit.

6 Jan 2010

BioMimetic Therapeutics amends and restates its agreement with Novartis Vaccines and Diagnostics

BioMimetic Therapeutics, Inc. today announced that effective December 31, 2009, the Company amended and restated its manufacturing and supply agreement with Novartis Vaccines and Diagnostics, Inc. for the supply of bulk rhPDGF-BB to BioMimetic.

6 Jan 2010

HHS introduces National Influenza Vaccination Week to raise awareness about flu vaccine

The U.S. Department of Health and Human Services has designated the week of January 10 through 16 as National Influenza Vaccination Week, in an effort to raise awareness about the importance of the flu vaccine.

6 Jan 2010

Oral cladribine to be the first oral disease-modifying multiple sclerosis therapy despite receiving RTF letter

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a recent "refuse to file" (RTF) letter issued by the Food and Drug Administration (FDA) regarding Merck Serono's oral cladribine has heightened the competition between oral cladribine and its primary competitor, Novartis/Mitsubishi Tanabe's FTY-720 (fingolimod), to be the first oral disease-modifying multiple sclerosis therapy to reach the market in the United States.

6 Jan 2010

LifeVantage receives formal approval to launch Protandim in Mexico

LifeVantage Corporation, the maker of science-based solutions to oxidative stress, announced today that the Company has received formal approval from the Mexican government to launch its flagship product, Protandim®, in Mexico. Initial shipments have cleared customs and Protandim® has been shipped to distributors in Mexico.

6 Jan 2010

Treatment with Effient more cost effective, show TRITON-TIMI 38 clinical trial results

Results from a health economic substudy of the TRITON-TIMI 38 clinical trial showed that among patients with acute coronary syndromes (ACS) managed with percutaneous coronary intervention (PCI), including stenting, treatment with Effient(®) (prasugrel) compared with branded clopidogrel (Plavix(®)) was more cost effective, and in most cases cost saving.

6 Jan 2010

CDC and AAFP recommend whooping cough vaccine for adults and adolescents

Many people may think of whooping cough as a disease of the past -- something eradicated generations ago. However, the number of cases reported by the Centers for Disease Control and Prevention (CDC) indicate that whooping cough (pertussis) is still very much a public health concern; health experts estimate that up to 600,000 cases occur each year in adults alone. In fact, whooping cough cases are on the rise in San Diego

6 Jan 2010

Special Notice announces BARDA's intentions to negotiate contract modification with PharmAthene

PharmAthene, Inc. a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, today commented on a Special Notice published by the US Department of Health and Human Services (DHHS), Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA) on December 29, 2009.

6 Jan 2010

Study reveals majority of drug companies utilize in-house call centers

Cutting Edge Information's most recent medical information study reveals that drug companies overwhelmingly agree that operating medical information call centers in-house is more efficient.

6 Jan 2010

Pharmaceutical News

Microbia creates carotenoids for food ingredient and nutritional supplement markets

CEI releases new diabetes market forecast study

Drug companies still under great and growing pressure to bring more products to market

ProFibrix B.V. receives loan up to $7.4 million to develop its new hemostat Fibrocaps

Teva Pharmaceutical Industries enters into two definitive agreements with AstraZeneca

Nutrient mix shows potential to improve memory in Alzheimer's patients

Flu vaccine safe but ineffective for RA patients treated with rituximab

Bogus drug manufactures embrace new tactics to dupe consumers

Watson Laboratories files ANDA to seek FDA's approval to market Nuvigil

Canada supports Mexico's pandemic response efforts

Developing countries reassess need for donated H1N1 vaccine

Pfizer and Strides Arcolab announce new collaboration

BioMimetic Therapeutics amends and restates its agreement with Novartis Vaccines and Diagnostics

HHS introduces National Influenza Vaccination Week to raise awareness about flu vaccine

Oral cladribine to be the first oral disease-modifying multiple sclerosis therapy despite receiving RTF letter

LifeVantage receives formal approval to launch Protandim in Mexico

Treatment with Effient more cost effective, show TRITON-TIMI 38 clinical trial results

CDC and AAFP recommend whooping cough vaccine for adults and adolescents

Special Notice announces BARDA's intentions to negotiate contract modification with PharmAthene

Study reveals majority of drug companies utilize in-house call centers

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News